recent post

ENTOD Pharmaceuticals ropes in Dr Anish Desai as Scientific & Research Adviser 

December 5, 2024
recent post

LPU's International Conference of Pharmacy 2024 discuss ways to transform pharma landscape

recent post

Akums Drugs & Pharmaceuticals partners with Caregen Co to launch speciality nutraceuticals 

recent post

Drug testing labs: Ensuring safety of medicines

recent post

Mahajan Imaging & Labs unveils AI-powered lab in Gurugram

ICPA Health Products introduces solution for oral, throat discomfort

ICPA Health Products introduces solution for oral, throat discomfort

Coolora Spray proves highly effective in reaching the tonsils and posterior pharyngeal wall, providing effective relief within just two minutes of application ICPA Health Products Ltd (ICPA) has introduced its newest oral healthcare solution – Coolora Spray. Specifically designed as a mouth spray, the product effectively addresses inflammatory and painful conditions in the mouth and throat, including post-tonsillectomy pain control, pharyngitis, laryngitis, oral mucositis, mouth ulcers and burning sensations.  Coolora Spray proves highly effective in reaching the tonsils and posterior pharyngeal wall, providing effective relief within just two minutes of application. Packed in a convenient 25 ml High-Density Polyethylene (HDPE) bottle equipped with a metered dose valve pump, a single spray delivers 250 micrograms of Benzydamine Hydrochloride. ICPA has expanded its product range with the introduction of Coolora spray, alongside the existing Coolora gargle.  A spray form of delivery brings unique benefits, especially in easing post-tonsillectomy surgical pain for patients who struggle with gargling after the surgery. Additionally, for children who have difficulty gargling, the spray would be more suitable because it eliminates the chances of gargle swallowing. This move reflects ICPA’s commitment to making healthcare more accessible for everyone. The active ingredient in Coolora Spray, Benzydamine Hydrochloride 0.15 per cent, belongs to the category of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Operating in the throat and mouth, the spray effectively alleviates pain and inflammation by inhibiting the synthesis of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β). Coolora Spray is suitable for both adults and children, with varying recommended dosages. For adults, it is advised to spray 4 to 8 puffs onto the affected area every 1½ to 3 hours. Children aged 6 to 12 years should administer four puffs, while those under six years old should apply one puff for every 4 kilograms of body weight, up to a maximum of four puffs, every 1½ to 3 hours.